Abstract:A user‐friendly protocol for the synthesis 3‐substituted coumarin derivatives was developed using Friedel‐Crafts alkylation and ozonolysis as key steps. Deactivation of 3‐chymotrypsin like protease (3CLpro) enzyme using these coumarin derivatives were investigated to explored their potential as 3CLpro inhibitors for Covid‐19 Therapeutics. The major threat to public health due to the outbreak of severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infection has been recognised as a global issue. The increase in morbidity is primarily due to the lack of SARS‐CoV‐2 specific drugs. One of the major strategies to combat this threat is to deactivate the enzymes responsible for the replication of corona virus. To this end, 3‐arylidene/3‐hydroxycoumarin induced deactivation of 3‐chymotrypsin like protease (3CLpro) enzyme, which takes the pivotal role in the replication and maturation, was investigated. For ready availability of the compounds for the above investigation, we have developed a user‐friendly protocol for the synthesis 3‐hydroxycoumarin derivatives from cheap and readily available starting materials in two steps; i) Bronsted acid catalysed Friedel‐Crafts alkylation of phenols with Morita‐Baylis‐Hillman adducts followed by intramolecular lactonization to trans‐3‐arylidenechroman‐2‐ones in one‐pot and ii) ozonolysis in reasonably good yields. Pharmacokinetic assessments of coumarin derivatives revealed drug‐like characteristics with moderate or low toxicity values. Notably, these hydroxycoumarins exhibited enhanced binding affinity against the 3CL protease of SARS‐CoV‐2, fitting well into the binding pocket akin to the previously studied inhibitor N3. Furthermore, a molecular dynamics study elucidated the dynamic behaviour of these small molecules when bound to the protein, showcasing intriguing complexities within the active site. Despite backbone variations and residual fluctuations, compounds 3 d–f and 6 a exhibited a consistent behaviour, instilling confidence in the therapeutic potential of these coumarins for combating SARS‐CoV‐2.

Chrysin 7-O-β-d-glucuronide, a Dual Inhibitor of SARS-CoV-2 3clpro and PLpro, for the Prevention and Treatment of COVID-19.

Discovery of Chalcone Derivatives As Bifunctional Molecules with Anti-SARS-CoV-2 and Anti-inflammatory Activities

Novel Alkynylamide-Based Nonpeptidic Allosteric Inhibitors for SARS-CoV-2 3-Chymotrypsin-like Protease

Schaftoside inhibits 3CLpro and PLpro of SARS-CoV-2 virus and regulates immune response and inflammation of host cells for the treatment of COVID-19

Investigating Derivatives of Tanshinone IIA Sulfonate Sodium and Chloroxine for Their Inhibition Activities Against the SARS-CoV-2 Papain-like Protease

Natural 7,8-secolignans from Schisandra sphenanthera fruit potently inhibit SARS-CoV-2 3CLpro and inflammation

An Integrated Method for Optimized Identification of Effective Natural Inhibitors Against SARS-CoV-2 3Clpro

Target-Based Virtual Screening and LC/MS-Guided Isolation Procedure for Identifying Phloroglucinol-Terpenoid Inhibitors of SARS-CoV-2

Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CLpro inhibitors for treating COVID-19

Sulforaphane is a reversible covalent inhibitor of 3‐chymotrypsin‐like protease of SARS‐CoV‐2

Study of Baicalin toward COVID-19 Treatment: In silico Target Analysis and in vitro Inhibitory Effects on SARS-CoV-2 Proteases.

The exploration of phytocompounds theoretically combats SARS-CoV-2 pandemic against virus entry, viral replication and immune evasion

Inhibitory Activity of Flavonoid Scaffolds on SARS-CoV-2 3CL pro : Insights from the Computational and Experimental Investigations

Screening of Botanical Drugs against SARS-CoV-2 Entry Reveals Novel Therapeutic Agents to Treat COVID-19

Discovery of highly potent covalent SARS-CoV-2 3CLpro inhibitors bearing 2-sulfoxyl-1,3,4-oxadiazole scaffold for combating COVID-19

Discovery of Novel SARS-CoV-2 3clpro Inhibitors from Natural Products by FRET-based Assay

Structure-based virtual screening methods for the identification of novel phytochemical inhibitors targeting furin protease for the management of COVID-19

Discovery, synthesis and mechanism study of 2,3,5-substituted [1,2,4]-thiadiazoles as covalent inhibitors targeting 3C-Like protease of SARS-CoV-2

Identification of Darunavir Derivatives for Inhibition of SARS-CoV-2 3Clpro

A Facile Synthesis of 3‐Substituted Coumarins and Investigation of Their 3CLpro Inhibition Activity Against SARS‐CoV‐2